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We report a strategy for the generation of heterodi-
meric protein conjugates using an unnatural amino
acid with orthogonal reactivity. This paper addresses
the challenges of site-specificity and homogeneity
with respect to the synthesis of bivalent proteins
and antibody-drug conjugates. There are numerous
antibody-drug conjugates in preclinical and clinical
development, yet these are based either on nonspe-
cific lysine coupling chemistry or on disulfide modifi-
cation made difficult by the large number of cyste-
ines in antibodies. Here, we describe a recombinant
approach that can be used to rapidly generate a
variety of constructs with defined conjugation sites.
Moreover, this methodology results in homogeneous
antibody conjugates whose biological, physical, and
pharmacological properties can be quantitatively
assessed and subsequently optimized. As proof of
concept, we have generated anti-Her2 Fab-Saporin
conjugates that demonstrate excellent potency
in vitro.
INTRODUCTION
Antibodies coupled to other ‘‘effector’’ molecules are of consid-
erable interest in oncology because of their ability to target tumor
cells with high specificity while delivering a cytotoxic payload.
Antibodies can be chemically coupled to potent natural or
synthetic toxins, or in the case of bispecific antibodies, one
arm can provide the binding function while the second arm can
provide the effector function, often through recruitment of cyto-
toxic T cells (Yamaizumi et al., 1978). Although considerable
effort is focused on the synthesis of effective antibody-drug
conjugates (ADCs), and exciting clinical results have been
obtained with trastuzumab-DM1 and brentuximab vedotin
(SGN-35) for breast cancer and Hodgkin lymphoma, respec-
tively, there still remain major challenges in the field (Presta,
2006; Senter, 2009). Even though there are a large number of
antibody drug conjugates in preclinical and clinical develop-Chemistry & Biology 18, 2ment, only three conjugated antibodies have been approved
by the Food and Drug Administration (FDA): anti-CD20-90Y
(Ibritumomab) and antiCD20 131I (Tositumomab) both for non-
Hodgkin lymphoma, and anti-CD33-calicheamicin (Gemtuzu-
mab Ozogamicin) for acute myelogenous leukemia (Wu and
Senter, 2005). Despite the promise of these ADCs, Gemtuzumab
Ozogamicin was recently pulled from themarket due to inactivity
and toxicity (Beck et al., 2010; Bross et al., 2001; Hamann et al.,
2002; Hollander et al., 2008; Senter, 2009). In general, coupling
of the toxin by amide bond formation with lysine side chains
results in nonspecific conjugation which can alter antigen
binding, physical properties, biological activity, or pharmacoki-
netics (Wu and Senter, 2005; Junutula et al., 2008). Moreover,
the inability to even define the structure and composition of
randomly labeled proteins (in contrast to the homogenous nature
of synthetic drugs) has been a significant challenge in optimizing
drug efficacy, safety, and manufacturing. There are some cases
where lysine free variants of proteins are engineered to alleviate
this problem; however this cannot be done without complicated
engineering (removal of multiple lysines) which can alter protein
binding and/or activity (Bachran et al., 2011). Cysteine labeling is
largely restricted to proteins without additional reactive cyste-
ines in order to prevent unwanted disulfide bridge formation, or
aggregation. If this requirement is not met, as can be the case
with antibodies, more complex labeling protocols to avoid reac-
tion with native cysteines must be performed, which can limit the
sites of conjugation, stability of conjugates or lead to challenges
in scale up (Schibli et al., 2002; Junutula et al., 2008).
Bispecific antibodies have recently been shown to have very
promising therapeutic activity, yet in most cases, multivalency
is limited to either naturally bivalent IgGs or fusion proteins
(Wolf et al., 2005). Fusion protein constructs require end-to-
end connection of two antibody coding regions; however, the
spatial proximity of the N termini of the variable heavy chain
(VH) and the variable light chain (VL) to the antigen binding site
may potentially affect antigen binding (Verma et al., 1998). The
production of bispecific antibodies can also pose significant
challenges as they are often inactive, or form unwanted aggre-
gates that may affect production and safety (Woo et al., 2006;
Zhou et al., 2007).
The availability of additional genetically encoded amino
acids with unique chemical reactivity may provide a solution to
many of these challenges. Previously we have site-specifically99–303, March 25, 2011 ª2011 Elsevier Ltd All rights reserved 299
Figure 1. Synthesis of a Site-Specific Anti-Her2 Fab-Sap 6 Heterodimer
An excess of aminooxy-maleimide linker is added to pAcPhe Herceptin Fab (blue/red). After purification, the toxin Sap 6 A157C (green) is added to the maleimide
functionalized Fab to create the anti-Her2-Sap heterodimer. See also Figure S1.
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Site-Specific Formation of Protein Heterodimersincorporated p-acetylphenylalanine (pAcPhe) and p-azidophe-
nylalanine into proteins in response to amber nonsense codons
in bacteria and mammalian cells (Wang et al., 2003, 2006;
Hutchins et al., 2011; Chin et al., 2002; Young et al., 2010). These
amino acids have orthogonal chemical reactivity to the canonical
twenty amino acids and can be conjugated efficiently and
selectively to alkoxyamines or alkynes, respectively, under mild
conditions. The site-specific introduction of a keto or azide
group into a surface exposed site in an antibody should allow
the selective conjugation of other proteins (antibodies, natural
toxins, etc.) or synthetic reagents (toxins, oligonucleotides,
metal chelators, etc.), while avoiding reaction with the native
disulfide bonds which are required for correct folding. Moreover,
the mutant proteins can be produced by recombinant methods
rapidly and on a large scale. As a proof of concept, we now
report the synthesis of a site-specific heterodimeric antibody-
toxin conjugate between the protein toxin saporin and Herceptin
(trastuzumab, anti-Her2) Fab that possesses high potency
in vitro.
RESULTS AND DISCUSSION
Mutant anti-Her2 Fab and Saporin Expression
Herceptin is an approved monoclonal antibody for the treatment
of Her2 overexpressing breast cancers (Ross et al., 2009).
pAcPhe was site-specifically introduced into Herceptin Fab
using an orthogonal amber suppressor aminoacyl-tRNA synthe-
tase/tRNA pair specific for pAcPhe. The previously reported
pBAD/pEVOL expression system was used to substitute
pAcPhe at a surface exposed site (K169 or S202) (Hutchins
et al., 2011; Young et al., 2010) and both have been shown to
have excellent coupling efficiencies with aminooxy modified
AlexaFluor 488 dye (Hutchins et al., 2011). Both the anti-Her2
K169pAcPhe and anti-Her2 S202pAcPhe mutant Fabs were
expressed in Escherichia coli in good yields (>1 mg/liter in shake
flasks), purified by Protein G chromatography, and their masses300 Chemistry & Biology 18, 299–303, March 25, 2011 ª2011 Elsevieconfirmed by electrospray ionization mass spectrometry (ESI-
MS) (see Figures S1A–S1B available online).
Saporin was used as the toxin partner as it is a highly cytotoxic
non-cell-permeable enzyme that functions as a ribosome-inacti-
vating protein (RIP) and has been used as an effector in targeting
EGFR positive cells (Chandler et al., 1998). A type 1 RIP, Saporin
6 (Sap 6), has been shown to have a genomic DNA fragmentation
activity in addition to its RNAN-glycosidase activity (Bagga et al.,
2003). Since Sap 6 does not contain any cysteines, we were able
to mutate an alanine to a cysteine residue in wild-type Saporin to
generate a uniquely reactive site for conjugation (pET-A157C).
When compared with wild-type expression in E. coli shake
flasks, we were able to obtain similar yields from the cysteine
mutant (1 mg/liter) (Pittaluga et al., 2005; Bonini et al., 2006).
The protein was purified by cation exchange (Mono S 5/50 GL)
and size exclusion chromatography (Superdex 75 10/300 GL).
The expected molecular weight (29 kDa) was confirmed by
SDS-page gel and ESI-MS (see Figures S1C and S1D).
Site-Specific Conjugation
To site-specifically crosslink the mutant Fab to saporin, we
synthesized a bifunctional aminooxy-maleimide linker that can
be selectively coupled to both the keto group of pAcPhe in
anti-Her2 and the thiol group of cysteine in Sap 6 (see Figure 1).
The desired compound was synthesized from commercial 6-
bromohexanol in five steps (see Supplemental Experimental
Procedures) (Defrancq and Lhomme, 2001; Toyokuni et al.,
2003; Berndt et al., 2007). The aminooxy-maleimide linker
(30 equiv.) was added to anti-Her2 K169pAcPhe Fab (100 mM)
in acetate buffer (pH 4.5) and after 16 hr, the conjugate was
confirmed by ESI-MS (see Figure 1E). It was then purified by
size exclusion chromatography (Superdex 75 10/300) and three
equivalents (240 mM) of Sap 6 A157C (reduced with TCEP resin)
were added for 3 hr at room temperature. The heterodimer was
purified using size exclusion chromatography (Superdex 200 10/
300 GL) (see Figures S2B–S2D). The coupling efficiency ofr Ltd All rights reserved
Figure 2. Characterization of Anti-HER2
K169pAcPhe Fab-Sap 6 A157C Heterodi-
meric Construct
Anti-Her2 K169pAcPhe Fab (lane 1) was conju-
gated to Sap 6 A157C (lane 2) as described in Fig-
ure 1 and the purified construct was analyzed by
reducing SDS-page and stained with Coomassie
(lane 3, A). The proteins were also transferred to
a nitrocellulose membrane and incubated with
anti-kappa-HRP (B) or anti-saporin-HRP (C). See
also Figure S2.
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Site-Specific Formation of Protein Heterodimersanti-Her2 K169pAcPhe to Sap 6 A157C was 50% (see Fig-
ure S2A). To verify the conjugation of Sap 6 to anti-Her2 Fab,
we performed a western blot with both anti-kappa (Figure 2B)
and anti-saporin antibodies (Figure 2C). Anti-Her2 Fab was
reduced to the light and heavy chains at the appropriate molec-
ular weight (25 kD) and the Her2 Fab-saporin construct was also
partially reduced. As depicted in the SDS-page gel in Figure 2,
lane 3, Saporin is correctly conjugated to the light chain of the
anti-Her2-Fab producing a molecule of 55 kDa. The molecular
weight of the heterodimer (77 kDa) was also confirmed by ESI-
MS (see Figure S1F). The versatile nature of this system allowed
us to easily generate another bivalent molecule using a different
mutant site in the herceptin Fab (anti-Her2 S202pAcPhe) with
a similar overall yield.
Cytotoxicity of anti-Her2 Fab-Saporin Heterodimer
We next tested the cytotoxicity of these heterodimeric conju-
gates with different human breast cancer cell lines. Anti-Her2
wild-type Fab and unconjugated Sap 6 A157C served as
controls. MDA-MB-435 cells (Chambers, 2009; Hollestelle and
Schutte, 2009) were transduced to express Her2 using a lentiviral
system; cells receiving an empty vector served as the control
(see Supplemental Experimental Procedures). Anti-Her2 conju-
gates or unconjugated proteins were added to cells at a concen-
tration range of 2.7 pM to 20 nM, and cell viability (OD405) was
measured after 4 days. As shown in Figure 3, both the anti-
Her2 wild-type Fab and Saporin 6 A157C have minimal, if any,
effect on either Her2 positive or Her2 negative cells. There is
only a minimal effect on cell viability by Saporin at the highest
concentration (20 nM). However, when Saporin is conjugated
to either anti-Her2 K169pAcPhe Fab or anti-Her2 S202pAcPhe
Fab a dramatic increase in the concentration dependent cyto-
toxicity was observed and the corresponding EC50’s were deter-
mined (197 and 154 pM, respectively). In the Her2 positive cell
line, there is almost complete cell death at >1 nMconcentrations,
while the majority of the cells are still viable in the Her2 negativeChemistry & Biology 18, 299–303, March 25, 2011cell line under similar conditions. The
EC50’s of both unconjugated anti-Her2
Fab and Saporin in both the positive and
negative cells lines are greater than the
highest concentration used (>20 nM).
Similar EC50’s were determined for the
anti-Her2-Sap conjugates in the Her2
negative cell line. In addition to these
cell lines, other lines (SKBR3, BCM2)
have been used and similar results wereobtained (see Figure S3). Thus, cytotoxicity is specific to Her2
expressing cells, and requires both components of the Her2-
Saporin conjugate.
SIGNIFICANCE
We have demonstrated that bivalent anti-Her2-Saporin
conjugates are very effective in vitro in inducing cell death
in Her2 positive breast cancer cells. We were also able
to combine the specificity of antibodies and the potency
of protein toxins using a bioorthogonal chemistry that
produced homogeneous heterodimeric conjugates in good
yields. These constructs and the resulting full-length anti-
body conjugates will next be tested in rodent xenograft
models. Using unnatural amino acid chemistry, we can
control the site of conjugation, create highly stable homoge-
neous conjugates, and combine the orthogonal reactivities
of the cysteine and pAcPhe moieties to create even more
complex conjugates. Moreover, with this recombinant-
based approach one can rapidly create numerous heterodi-
meric constructs with different toxins and antibodies to
determine the optimal conjugation partner, site, and linker
to create the most effective therapeutic agents.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
To express Saporin 6 A157C, plasmid pET-SapA157C (which encodes a
Saporin 6 gene with a cysteine mutant and an ampicillin-resistant gene) was
transformed into BL21(DE3) pLysS E. coli. Cells were amplified in 2YT media
(5ml) supplementedwith ampicillin (50 mg/ml) and chloramphenicol (40 mg/ml).
Cells were grown to saturation and inoculated 1:100 in 2YT expression
media at 37C (250–270 rpm shaker). At an OD of 0.6–0.8, the cells were
induced with 1 mM IPTG and continued shaking at 37C for 4 hr. The cells
were centrifuged (6000 3 g; 10 min) and resuspended in 40 ml lysis buffer
(20 mM Tris, [pH 8.0], 2 mM EDTA, complete protease inhibitor tablet (Roche),
and 1–5 mM DTT) per 1 liter culture. The sample was sonicated on ice (10 min
process time, 30 s on, 30 s off) and centrifuged at 30,000 3 g for 20 min.ª2011 Elsevier Ltd All rights reserved 301
Figure 3. Cell Viability Assay with Anti-
Her2 pAcPhe Fab-Sap 6 A157C Bivalent
Constructs
Anti-Her2 Fab-Sap heterodimeric constructs and
controls were incubated with MDA-MB-435 cells
and the OD405 (p-nitrophenyl phosphate, pNPP)
was read after 4 days. Concentrations of samples
range from 2.7 pM to 20 nM.
(A) Her2 positive cell line.
(B) Her2 negative cell line.
See also Figure S3.
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concentrated by Amicon concentrator (10 kDa MWCO), 1 mM dithiothreitol
(DTT) was added, and sample was purified by size exclusion chromatography
(Superdex 75 10/300 GL). Anti-Her2 Fabs were expressed and purified as
described previously (Hutchins et al., 2011).
Site-Specific Conjugation
Fab (100 mM) (anti-Her2 K169pAcPhe) was reacted with 3 mM crosslinker in
100 mM acetate buffer (pH 4.5) at 37C. After 16 hr, the conjugate was purified
by size exclusion chromatography (Superdex 75 10/300 GL). Sap-6 (A157C)
was then reduced using TCEP resin (2 h) and 240 mM protein was added
to 80 mM Fab-linker in PBS (pH 7.5) for 3 hr at room temperature. The
coupled protein was purified using size exclusion chromatography (Superdex
200 10/300 GL) and resolved on reducing SDS-page and stained with302 Chemistry & Biology 18, 299–303, March 25, 2011 ª2011 ElsevieCoomassie (Figure 2, a), or transferred to nitrocellulose and probed with
anti-kappa-HRP (Sigma, 1:5000 dilution) or anti-saporin-HRP (Advanced
Targeting Systems, 1:2000 dilution) in 3% dry milk (BioRad) in PBST
(0.05% Tween). Membranes were developed colorimetrically using the metal
enhanced DAB kit (Pierce).
Cell Viability Assay
Human tumor cells were seeded into 96-well plates at 5000 cells/well in
complete EMEM medium containing 10% FBS. The cells were allowed to
attach for 2 hr at 37C before adding Her2 Fab conjugates or controls at
a concentration range from 0 to 20 nM. After 4 days, the cells were washed
and lysed with 1% Triton X-100. The number of live cells was determined
based on phosphatase activity measured photometrically after incubation
with p-nitrophenyl phosphate (pNPP, Sigma).r Ltd All rights reserved
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